Cetuximab Antibody Kit ELISA

Détails pour le produit réf. ABIN2964868, Fournisseur: Connectez-vous pour afficher
Antigène
Reactivité
Humain
Alternatives
Kits with alternative reactivity to:
4
1
Type de méthode
Sandwich ELISA
Application
ELISA
Options
Fournisseur
Connectez-vous pour afficher
N° du produit (Fournisseur)
Connectez-vous pour afficher
Fonction The kit is a sandwich assay for the qualitative determination of antibodies against cetuximab in serum and plasma samples.
Marque SHIKARI®
Type d'échantillon Plasma (EDTA), Plasma (heparin), Serum
Analytical Method Qualitative
Méthode de détection Colorimetric
Ingrédients 96 well plate, monoclonal antibody, Reactive and Negative controls, wash buffer, assay buffer, TMB substrate, conjugate, stop buffer, Adhesive film
Matériel non inclus 1. Micropipettes (< 3 % CV) and tips to deliver 5-1000 μL.
2. Calibrated measures.
3. Tubes (1 mL) for sample dilution.
4. Wash bottle, automated or semi-automated microtiter plate washing system.
5. Microtiter plate reader capable of reading absorbance at 450/650 nm.
6. Bidistilled or deionised water, paper towels, pipette tips and timer.
Antigène
Classe de substances Antibody
Sujet Cetuximab (IMC-C225, Erbitux) is a chimeric monoclonal antibody of the immunoglobulin G1 (IgG1) and FDA-approved epidermal growth factor receptor (EGFR) inhibitor. It is a 152 kDa protein composed of four polypeptide chain. There are 32 cysteine residues forming accordingly 16 potential disulfide bonds. Preclinical studies have shown that cetuximab enhances the antitumour effects of chemotherapy (e.g. that of irinotecan in colorectal cancer) as well as radiotherapy (e.g. in squamous cell carcinoma of the head and neck) by inhibiting cell proliferation, angiogenesis and metastasis and by promoting apoptosis is used for the treatment of metastatic colorectal cancer, metastatic non-small cell lung cancer and head and neck cancer. Cetuximab also blocks growth factor-induced activation of the downstream mitogen-activated protein kinase, inhibiting cell proliferation. It has been also illustrated that cetuximab increases the receptor internalization which is another mechanism to silence the receptor. Cetuximab arrests cell cycle at G1 gap phase by upregulating antiproliferative p27-kip1, which functions via complex formation with Cdk2, and downregulating proliferating cell nuclear antigen (PCNA). It also decreases angiogenic factors, inhibits tumor-cell invasion and metastasis via downregulation of matrix metalloproteinases (MMPs) and VEGF, and promotes apoptosis by upregulating apoptotic protein, Bax, with the help of other chemotherapeutic agents. Cetuximab has been widely shown to display synergistic effect with other agents and/or radiotherapy. Binding of antigen-binding fragment (Fab) of Cetuximab, which displays higher affinity comparing to ligands of EGFR, takes place via domain III of extracellular EGFR, preventing the receptor from conformational change to be dimerized and blocking EGFR signaling through inhibition of EGF and TGF-alpha-stimulated phosphorylation of the receptor.
Indications d'application Target: anti drug antibody
Estimates biological levels in human, mouse, rat and monkey serum or plasma samples.
Commentaires

Qualitative Screening ADA

Volume d'échantillon 10 μL
Durée du test 2.5 h
Plaque Pre-coated
Protocole The Antibody to cetuximab (Erbitux®) ELISA is a sandwich assay for the determination of antibodies against cetuximab in serum and plasma samples. During the first incubation period, antibodies to cetuximab (ATC) in patient serum/plasma samples are captured by the drug cetuximab (Erbitux®) coated on the wall of the microtiter wells. After washing away the unbound components from samples, a peroxidase-labelled specific conjugate is added to each well and then incubated. After a second washing step, the bound enzymatic activity is detected by addition of tetramethylbenzidine (TMB) chromogen-substrate. Finally, the reaction is terminated with an acidic stop solution. The intensity of the reaction color is directly proportional to the concentration of ATC in sample.
Calcul des résultats

The results are evaluated by a cut-off value which is estimated by multiplying the mean OD450/650nm of the negative controls by 3.

Restrictions For Research Use only
Buffer < 0.1 % sodium azide
Agent conservateur Sodium azide
Précaution d'utilisation This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.
Stock 4 °C
Stockage commentaire The kit is shipped at ambient temperature and should be stored at 2-8°C. Keep away from heat or direct sun light. The strips of microtiter plate is stable up to the expiry date of the kit in the broken, but tightly closed bag when stored at 2-8°C.
Date de péremption 12 months
Avez-vous cherché autre chose?